Methicillin-Susceptible Staphylococcus Aureus (MSSA) Market : Size, Share, Emerging Trends, Analysis and Forecasts to 2020

Press Release
Methicillin-susceptible staphylococcus aureus (MSSA) infections are the infections caused by gram-positive bacterium. Staphylococcus aureus is the common pathogen in the skin, bone, central nervous system, pulmonary and soft tissues. These bacteria produce beta-lactamase which is the major cause of the infection. MSSA infection may lead to the skin allergies, pneumonia and endocarditis. Methicillin-susceptible staphylococcus aureus market is segmented on the basis of the treatment methods used for treating infections which are as follows:
  • Semi-synthetic penicillin (intravenous oxacillin, intravenous nafcillin, oral dicloxacilin)
  • Cephalosporins (oral cephalexin, intravenous cefazolin)
  • Vancomycin (vanocin)
  • Linezolid (Zyvox)
  • Daptomycin (Cubicin)

Obtain Report Details @

Semi synthetic penicillin captures the major share of the market followed by the cephalosporins. However Vancomycin is only used when patient is allergic to penicillin. In normal conditions, vancomycin is avoided because the rate of action of these drugs is slow in comparison to others and overuse of vancomycin leads to the development of vancomycin resistant staphylococcus aureus bacteria inside the body. Linezolid and Deptomycin are prescribed by the doctors when the MSSA leads to skin and soft tissue infection and pneumonia in children and adults.
Enquiry for Discount on this Report @
Methicillin-susceptible staphylococcus aureus (MSSA) market is growing at faster pace majorly due to increasing rate of morbidity and mortality of the MSSA infection. Additionally, the extensive research and development activities with respect to the development of the more efficient and less time consuming drugs is also driving the market of methicillin-susceptible staphylococcus aureus. As for instance, a study performed at the John Radcliffe Hospital, Oxford, U.K., shows that MSSA infection has mortality rate of 27%. Therefore, there is an excessive need to develop novel drugs which could help in treating MSSA infection. Cellcutix Corporation has developed a drug by the name Brilacidin, which acts against the acute bacterial skin and skin structure infection (ABSSSI), caused by the MSSA. This drug is currently under phase II clinical trials and it is expected that this drug will help the methicillin-susceptible staphylococcus market to grow.
Request Report Brochure @

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]


Related Articles